REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients

REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.

FDA Approves First Drug to Treat Dementia-Associated Agitation in

First FDA Approved Medication for Agitation Associated with

FDA Approves First Drug for Treating Agitation in Alzheimer's

FDA approves first drug for agitation due Alzheimer's dementia

REXULTI® (brexpiprazole) For Healthcare Professionals

Otsuka and Lundbeck Receive the US FDA's Approval for Rexulti

For Alzheimer's Agitation, Promising News from Rexulti

These highlights do not include all the information needed to use

This Antipsychotic Drug Can Now Be Used to Treat Agitation in

Otsuka and Lundbeck Announce REXULTI for Alzheimer's Agitation

Antipsychotic Drug Reduces Alzheimer's-Associated Agitation

FDA OKs First Drug for Agitation in Alzheimer's Dementia